ATE183196T1 - Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen - Google Patents

Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Info

Publication number
ATE183196T1
ATE183196T1 AT94902266T AT94902266T ATE183196T1 AT E183196 T1 ATE183196 T1 AT E183196T1 AT 94902266 T AT94902266 T AT 94902266T AT 94902266 T AT94902266 T AT 94902266T AT E183196 T1 ATE183196 T1 AT E183196T1
Authority
AT
Austria
Prior art keywords
fibronectin
collagen
binding proteins
peptide inhibitors
related collagen
Prior art date
Application number
AT94902266T
Other languages
English (en)
Inventor
David D Roberts
Henry C Krutzch
John M Sipes
Neng-Hua Guo
Eric Negre
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE183196T1 publication Critical patent/ATE183196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94902266T 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen ATE183196T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/973,235 US5491130A (en) 1992-11-10 1992-11-10 Peptide inhibitors of fibronectin and related collagen-binding proteins

Publications (1)

Publication Number Publication Date
ATE183196T1 true ATE183196T1 (de) 1999-08-15

Family

ID=25520653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902266T ATE183196T1 (de) 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Country Status (8)

Country Link
US (2) US5491130A (de)
EP (1) EP0669937B1 (de)
JP (2) JP3789931B2 (de)
AT (1) ATE183196T1 (de)
AU (1) AU683234B2 (de)
CA (1) CA2148383A1 (de)
DE (1) DE69326016T2 (de)
WO (1) WO1994011395A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509703A (ja) * 1993-03-12 1996-10-15 ゾーマ コーポレイション 殺菌／透過性増加タンパク質産物の治療用途
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
DE69734601T2 (de) 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20020169108A1 (en) * 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9903408D0 (en) * 1999-02-15 1999-04-07 Oxford Biomedica Ltd Peptides
JP2003502019A (ja) * 1999-04-16 2003-01-21 チルドレンズ メディカル センター コーポレーション 接着調節ペプチドおよび使用のための方法
CN1301723A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——纤维结合蛋白类型ii10和编码这种多肽的多核苷酸
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
CN1246333C (zh) * 2000-09-07 2006-03-22 舍林股份公司 EDb－纤粘连蛋白结构域(II)的受体
EP1224943A1 (de) * 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin als Tumor Marker, detektiert durch auf Phagen exprimierte Antikörper
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
WO2004101598A2 (en) * 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
JP2008514900A (ja) * 2004-07-30 2008-05-08 アデザ・バイオメデイカル・コーポレイシヨン 疾病および他の状態のマーカーとしての癌胎児性フィブロネクチンならびに癌胎児性フィブロネクチンの検出のための方法
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
KR101597391B1 (ko) 2009-10-15 2016-02-24 클라라산스, 인크. 인플루엔자 치료용 재조합 사람 ｃｃ10 단백질
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
EP2836591B1 (de) 2012-04-09 2018-06-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur erzeugung pluripotenter und multipotenter zellen
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3125907A4 (de) 2014-04-01 2017-11-29 Cornell University Verwendung von doppelsträngiger dna in exosomen: neuartiger biomarker zur krebsdetektion
FR3024364B1 (fr) 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001013A4 (fr) * 1987-10-22 1989-06-13 Icp Internat Inst Of Cellular Derives de synergimycines de types a et b, procede pour leur preparation et utilisation de ceux-ci.
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin

Also Published As

Publication number Publication date
EP0669937B1 (de) 1999-08-11
JP2006028195A (ja) 2006-02-02
JPH08510715A (ja) 1996-11-12
DE69326016T2 (de) 2000-04-13
AU5669594A (en) 1994-06-08
JP3789931B2 (ja) 2006-06-28
CA2148383A1 (en) 1994-05-26
EP0669937A1 (de) 1995-09-06
AU683234B2 (en) 1997-11-06
US5491130A (en) 1996-02-13
WO1994011395A1 (en) 1994-05-26
US5849701A (en) 1998-12-15
DE69326016D1 (de) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69326016D1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
ATE196428T1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE69812630D1 (de) Integrinbindendes peptid und dessen verwendung
ATE548455T1 (de) Zelldurchlässige peptidhemmer des jnk- signaltransduktionsweges
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
ES2061733T3 (es) Nuevos derivados peptidicos inhibidores de la agregacion de plaquetas.
DE59609235D1 (de) Verwendung von aerogelen in der landwirtschaft
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DK0835447T3 (da) Peptider og sammensætninger, der modulerer apoptose
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
WO2000048625A3 (en) Inhibitors for use in hemostasis and immune function
ATE191223T1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander
DE69919684D1 (de) Verwendung von isolierten domänen des type-iv-kollagens zur änderung der zell- und gewebewechselwirkung
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
MY109158A (en) Modified platelet factor-4.
Daramola et al. Detection of fibronectin expression by human endothelial cells using a enzyme-linked immunosorbent assay (ELISA): enzymatic degradation by activated plasminogen
ES2109487T3 (es) Analogos de tetrapeptidos parcialmente modificados y retroinvertidos de fragmentos de proteina c-reactiva.
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.
ATE87207T1 (de) Azapropazon zur praevention von post-ischaemischem gewebeschaden.